Literature DB >> 20106512

Quality of care in advanced ovarian cancer: the importance of provider specialty.

Cheryl Mercado1, David Zingmond, Beth Y Karlan, Evan Sekaris, Jenny Gross, Melinda Maggard-Gibbons, James S Tomlinson, Clifford Y Ko.   

Abstract

BACKGROUND: One of the cornerstones of ovarian cancer therapy is cytoreductive surgery, which can be performed by surgeons with different specialty training. We examined whether surgeon specialty impacts quality of life (as proxied by presence of ostomy) and overall survival for women with advanced ovarian cancer.
METHODS: Stage IIIC/IV ovarian cancer patients were identified using 4 state cancer registries: California, Washington, New York, and Florida and linked records to the corresponding inpatient-hospital discharge file, AMA Masterfile, and 2000 U.S. Census SF4 File. Predictors of receipt of care by a general surgeon and creation of fecal ostomy were analyzed. Multivariate modeling was performed to assess the association of hospital volume (low volume (LV) [0-4 cases], middle volume (MV) [5-9], high volume (HV) [10-19], and very high volume (VHV) [20+]) and surgeon specialty training (gynecologic oncologists/gynecologists, general surgeons, and other specialty) on survival.
RESULTS: We identified 31,897 Stage IIIC/IV patients; mean age was 64 years. Treatment of patients by a general surgeon was predicted by LV, rural patient residence, poverty, and high level of comorbidity. Patients had lower hazard of death when treated in higher volume hospitals as compared to LV [VHV hazard ratio (HR)=0.79, P<.0001; HV HR=0.89, P<0.001]. Patients treated by a general surgeon had higher likelihood of an ostomy (OR=4.46, P<.0001) and hazard of death (HR=1.63, P<.0001) compared to gynecologic oncologist/gynecologist.
CONCLUSIONS: Advanced stage ovarian cancer patients have better survival when treated by gynecologic oncology/gynecology trained surgeons. Data suggest that referral to these specialists may optimize surgical debulking and minimize the creation of a fecal ostomy. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20106512     DOI: 10.1016/j.ygyno.2009.12.033

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Racial disparities and patterns of ovarian cancer surgical care in California.

Authors:  F W Liu; L M Randall; K S Tewari; R E Bristow
Journal:  Gynecol Oncol       Date:  2013-09-07       Impact factor: 5.482

Review 2.  Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.

Authors:  Iván Díaz-Padilla; Albiruni Ryan Abdul Razak; Lucas Minig; Marcus Q Bernardini; Josep María Del Campo
Journal:  Clin Transl Oncol       Date:  2012-01       Impact factor: 3.405

Review 3.  Is It Time to Centralize Ovarian Cancer Care in the United States?

Authors:  Renee A Cowan; Roisin E O'Cearbhaill; Ginger J Gardner; Douglas A Levine; Kara Long Roche; Yukio Sonoda; Oliver Zivanovic; William P Tew; Evis Sala; Yulia Lakhman; Hebert A Vargas Alvarez; Debra M Sarasohn; Svetlana Mironov; Nadeem R Abu-Rustum; Dennis S Chi
Journal:  Ann Surg Oncol       Date:  2015-10-28       Impact factor: 5.344

4.  Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers.

Authors:  Robert C Bast; Steven Skates; Anna Lokshin; Richard G Moore
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

5.  Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass.

Authors:  Richard G Moore; M Craig Miller; Paul Disilvestro; Lisa M Landrum; Walter Gajewski; John J Ball; Steven J Skates
Journal:  Obstet Gynecol       Date:  2011-08       Impact factor: 7.661

6.  Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.

Authors:  Valerie B Galvan-Turner; Jenny Chang; Argyrios Ziogas; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2015-09-24       Impact factor: 5.482

7.  Disparities in ovarian cancer care quality and survival according to race and socioeconomic status.

Authors:  Robert E Bristow; Matthew A Powell; Noor Al-Hammadi; Ling Chen; J Philip Miller; Phillip Y Roland; David G Mutch; William A Cliby
Journal:  J Natl Cancer Inst       Date:  2013-03-28       Impact factor: 13.506

8.  Leucine-rich alpha-2-glycoprotein-1 is upregulated in sera and tumors of ovarian cancer patients.

Authors:  John D Andersen; Kristin Lm Boylan; Ronald Jemmerson; Melissa A Geller; Benjamin Misemer; Katherine M Harrington; Starchild Weivoda; Bruce A Witthuhn; Peter Argenta; Rachel Isaksson Vogel; Amy Pn Skubitz
Journal:  J Ovarian Res       Date:  2010-09-10       Impact factor: 4.234

Review 9.  The optimal organization of gynecologic oncology services: a systematic review.

Authors:  M Fung-Kee-Fung; E B Kennedy; J Biagi; T Colgan; D D'Souza; L M Elit; A Hunter; J Irish; R McLeod; B Rosen
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

10.  Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.

Authors:  Britt K Erickson; Jovana Y Martin; Monjri M Shah; J Michael Straughn; Charles A Leath
Journal:  Gynecol Oncol       Date:  2014-02-08       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.